---
title: "IPH: Three late-stage oncology assets drive value, with major partnerships and pivotal data due in H2 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295950027.md"
description: "Focused on oncology, the company advances three key assets: lacutamab (targeting CTCL with strong Phase 2 data and a major Sobi partnership), monalizumab (in Phase 3 for NSCLC with AstraZeneca), and IPH4502 (a novel ADC in Phase 1). Significant milestones and data readouts are expected in H2 2026.Original document: Innate Pharma SA Class A [IPH] Slides Release — Aug. 14 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-14T14:45:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295950027.md)
  - [en](https://longbridge.com/en/news/295950027.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295950027.md)
---

# IPH: Three late-stage oncology assets drive value, with major partnerships and pivotal data due in H2 2026

Focused on oncology, the company advances three key assets: lacutamab (targeting CTCL with strong Phase 2 data and a major Sobi partnership), monalizumab (in Phase 3 for NSCLC with AstraZeneca), and IPH4502 (a novel ADC in Phase 1). Significant milestones and data readouts are expected in H2 2026.

Original document: Innate Pharma SA Class A \[IPH\] Slides Release — Aug. 14 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [IPHA.US](https://longbridge.com/en/quote/IPHA.US.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [REG - AstraZeneca PLC - Update on eVOLVE-Lung02 Phase III trial](https://longbridge.com/en/news/296062318.md)
- [AstraZeneca halts lung cancer trial of volrustomig in latest blow to pipeline](https://longbridge.com/en/news/296069146.md)
- [ADCT: Q2 2026 delivered stable sales, improved losses, and regulatory challenges for ZYNLONTA](https://longbridge.com/en/news/295792223.md)
- [AstraZeneca: Tagrisso Plus Orpathys Phase III Trial Shows PFS, OS Improvements In EGFRm Lung Cancer](https://longbridge.com/en/news/296071807.md)
- [Innate Pharma Secures €30M, Extends Cash Runway Into 2028](https://longbridge.com/en/news/295966041.md)